Literature DB >> 14736767

Expression of protein gene product 9.5 in lepromatous eyes showing ciliary body nerve damage and a "dying back" phenomenon in the posterior ciliary nerves.

G J Ebenezer1, E Daniel.   

Abstract

BACKGROUND/AIM: Peripheral nerve destruction is the hallmark of leprosy. Ocular complications form a substantial part of the clinical manifestations but histopathology of nerve destruction within ocular structures has not been shown satisfactorily. The role of protein gene product (PGP) 9.5 in identifying nerve destruction in the ciliary body and posterior ciliary nerves of lepromatous eyes is shown.
METHODS: Serial sections from two lepromatous eyes and two non-lepromatous eyes were stained with PGP 9.5. Histopathological comparison was done on the expression of the PGP 9.5 stain in nerves within the ciliary body, posterior ciliary nerves adjacent to the optic nerve, and nerves tracking through the sclera.
RESULTS: In non-lepromatous eyes, PGP 9.5 was expressed in nerves within the ciliary body, the nerves within the sclera, and posterior ciliary nerves adjacent to the optic nerve. In lepromatous eyes no PGP 9.5 was expressed, signifying nerve destruction.
CONCLUSIONS: Nerve destruction in lepromatous eyes has been confirmed histopathologically by the absence of or patchy staining with PGP 9.5. Nerve destruction in the ciliary body can extend to the posterior ciliary nerves by an ascending axonopathy. This "dying back" phenomenon is akin to the "glove and stocking" anaesthesia found in lepromatous leprosy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736767      PMCID: PMC1771971          DOI: 10.1136/bjo.2003.027276

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  Pathology of a lepromatous eye.

Authors:  G J Ebenezer; E Daniel
Journal:  Int J Lepr Other Mycobact Dis       Date:  2000-03

Review 2.  Leprosy elimination-a virtual phenomenon or a reality?

Authors:  Diana N J Lockwood
Journal:  BMJ       Date:  2002-06-22

3.  Disorders of peripheral cutaneous nerves.

Authors:  G Weddell
Journal:  J Invest Dermatol       Date:  1977-07       Impact factor: 8.551

4.  The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase.

Authors:  K D Wilkinson; K M Lee; S Deshpande; P Duerksen-Hughes; J M Boss; J Pohl
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

5.  PGP9.5 as a prognostic factor in pancreatic cancer.

Authors:  E Tezel; K Hibi; T Nagasaka; A Nakao
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

6.  PGP 9.5--a new marker for vertebrate neurons and neuroendocrine cells.

Authors:  R J Thompson; J F Doran; P Jackson; A P Dhillon; J Rode
Journal:  Brain Res       Date:  1983-11-14       Impact factor: 3.252

7.  Morphology and neurochemistry of canine corneal innervation.

Authors:  C F Marfurt; C J Murphy; J L Florczak
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

8.  Expression of protein gene product 9.5 in the anterior lens epithelial cells of atopic cataracts.

Authors:  Junko Nakajima; Atsushi Mekada; Jiro Nakamura; Yasuhiro Nishida; Yoshimitsu Tokunaga
Journal:  J Cataract Refract Surg       Date:  2002-11       Impact factor: 3.351

9.  PGP9.5 as a candidate tumor marker for non-small-cell lung cancer.

Authors:  K Hibi; W H Westra; M Borges; S Goodman; D Sidransky; J Jen
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

10.  Epithelioid granuloma in the iris of a lepromatous leprosy patient; an unusual finding.

Authors:  E Daniel; G J Ebenezer; T J ffytche; A Sigamani; C K Job
Journal:  Int J Lepr Other Mycobact Dis       Date:  2000-06
View more
  2 in total

Review 1.  Treatment and Evaluation Advances in Leprosy Neuropathy.

Authors:  Gigi J Ebenezer; David M Scollard
Journal:  Neurotherapeutics       Date:  2021-11-19       Impact factor: 7.620

2.  Changes in ocular aquaporin-4 (AQP4) expression following retinal injury.

Authors:  Adnan Dibas; Ming-Hui Yang; Shaoqing He; Joseph Bobich; Thomas Yorio
Journal:  Mol Vis       Date:  2008-09-25       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.